Advancing Cell Therapeutics

Tacitus Therapeutics is a clinical-stage biotechnology company developing advanced medicines for treatment of blood cancers, immune disorders, and other intractable disease conditions. Our mission is to pioneer best-in-class therapies using proprietary cell expansion, differentiation, and engineering platform technologies that overcome the limitations of traditional cell transplantation. Initial targets include a lead clinical program (HSC100) investigating the treatment of blood cancers, followed by preclinical programs to address clotting disorders and other serious unmet medical needs.

Tacitus Therapeutics’ guiding principle is to focus development efforts on next-gen stem cell therapies that offer curative potential, a clear underlying mechanism of action, and potential for future improvements. To achieve this we bring together leading experts and partnered institutions alongside our platform technology for stem cell expansion, differentiation, and engineering.

Potential Applications

  • Dendritic Cells for Vaccines
  • T-Cell Product for CAR-T Therapy
  • Source of Stem Cells
  • Cells for Gene Editing

Current Programs


Our lead program, HSC100, is an investigational umbilical cord blood-expanded allogeneic hematopoietic stem cell (HSC) therapy. HSC100 is being investigated in an open-label Phase I clinical trial in the U.S.1 for the treatment of hematological malignancies in up to 17 patients.


Our second program, MEG100, is an umbilical cord blood-differentiated allogeneic megakaryocyte (MEG) therapy in pre-clinical development. MEG are specialized cells that form platelets that are involved in clotting.


Overcoming Challenges

Our proprietary technology includes the use of an epigenetic modifier, valproic acid (VPA), to expand the number and the quality of HSCs found in cord blood collections. Our proprietary cell expansion platform overcomes current limitations in transplantation resulting from the inability to find matched donors, graft versus host disease, long engraftment times, and graft rejections.

The current supply of platelet transfusion products from volunteer donors have a limited shelf life of ten days, is not scalable to growing demand, and carries the risk of alloimmunization or contaminating pathogens. MEG100 uses a proprietary scalable cell culture technology to produce a cryopreservable megakaryocyte therapeutic product that can be stored long-term. The technology enables the manufacture of MEGs with curative potential by producing platelets within the patients’ own bodies naturally after infusion.

1The trial is being conducted at The Mount Sinai Hospital